With Novartis AG's root-to-branch revamp a reality, its American CEO Joseph Jimenez is passing the leadership baton to the Swiss group's chief medical officer Vasant Narasimhan – another American who has been increasingly at the center of its drug development and commercialization strategy and who is a big proponent of automation and artificial intelligence in future discovery.
News of Jimenez's departure - effective Feb. 1, 2018 - came as a surprise to the industry, and comes after...





